Q4 Company

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

10/4/2023

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced that its Chief Executive Officer James Rolke will be presenting at the upcoming **2023 ROTH Healthcare Opportunities Conference** being held in New York, NY on October 12, 2023. Mr. Rolke will also be participating in one-on-one investor meetings at the conference.

Roth 2023 Healthcare Opportunities Conference

Date: Thursday, October 12, 2023
Time: 8:45 a.m. Eastern Time
Location: Tap Room - 3rd Floor @ The Yale Club, New York, NY
Register: https://www.meetmax.com/sched/event_95633/conference_register.html

Please contact your ROTH representative to schedule one-on-one meetings with the management team during the conference.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. Revelation's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD) and its well-established effect on the innate immune system. Our two lead programs include evaluating Gemini as a potential therapy for the treatment of acute and

chronic organ disease including acute kidney injury (AKI), chronic kidney disease (CKD) and myocarditis (REVTx-300) and as a potential prevention and treatment of hospital acquired infection (REVTx-100).

For more information on Revelation, please visit **www.RevBiosciences.com**.

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences, Inc.

Email: **svedrick@revbiosciences.com**

and

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences, Inc.

Email: **czygmont@revbiosciences.com**

Source: Revelation Biosciences Inc.